Tardive Dyskinesia: 8-Question Quiz on What We Know

References

1. Kane JM, Smith JM. Tardive Dyskinesia Prevalence and Risk Factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39(4):473-481.

2. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry 2017;78(3):e264-e278.

3 Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21-27.

4 Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Movement Disord. 2009;24(16):2309-2315.

5 Zai CC, Maes MS, Tiwari AK, et al. Genetics of tardive dyskinesia: Promising leads and ways forward. J Neurol Sci. 2018;389:28-34.

6 Zai CC, Lee FH, Tiwari AK, et al. Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis. Front Pharmacol. 2018;9:974.

7. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2, and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry. 2008;13:544-556.

8. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics. 2005;15:151-158.

9. The American Psychiatric Association Practice Guideline for The Treatment of Patients With Schizophrenia, Third Edition. 2021. https://doi.org/10.1176/appi.books.9780890424841

10. Bergman H, Bhoopathi PS, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Jan 20;1(1):CD000205.

11. El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1(1):CD000458.

12. Soares-Weiser K, Maayan N, Bergman H. Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1(1):CD000209

13. Soares-Weiser K, Rathbone J, Ogawa Y, et al. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 19;3:CD000208.

14. Ad1elufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2015 Apr 13;(4):CD010501.

15. Kane JM, Smith JM. Tardive dyskinesia prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473-481.

16. Caroff SN, Leong SH, Roberts C, et al. Cumulative Burden of Illness in Veterans With Tardive Dyskinesia and Serious Mental Disorders. J Clin Psychopharmacol. 2020;40:38-45.

17. Carroll B, Irwin DE. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia. J Manag Care Spec Pharm. 2019;25:810-816.

18. Guy W. ECDEU assessment manual for psychopharmacology: revised. DHEW Publication No. ADM 76-338. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976: 534-537.

19. Chouinard G, Ross-Chouinard A, Annable L, Jones B. The extrapyramidal symptom rating scale. Can J Neurol Sci. 1980;7(3):233.

20. Kalachnik JE, Sprague RL. The dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations. J Clin Psychol. 1993;49(2):177-189.

21. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61(Suppl.)4:5-9.

22. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50:541-547.

23. Blanchet PJ, Parent M-T, Rompre PH, Levesque D. Relevance of animal models to human tardive dyskinesia. Behav Brain Funct. 2012;8:12.